Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

April 1, 2025

Conditions

Locally Advanced Rectal Cancer

Interventions

RADIATION

radiation

45 Gy radiation dose in 25 fractions to the pelvis

DRUG

PD-1 Monoclonal Antibody

200mg Sintilimab after radiation (3 times, 2-week interval)

PROCEDURE

TME surgery

TME surgery for 6\~8 weeks after radiation

Trial Locations (1)

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Peking University People's Hospital

OTHER